On March 29, 2020 the U.S. Department of Health and Human Services issued a statement that they have “accepted 30 million doses of hydroxychloroquine sulfate donated by Sandoz, the Novartis generics and biosimilars division, and one million doses of chloroquine phosphate donated by Bayer Pharmaceuticals, for possible use in treating patients hospitalized with COVID-19 or for…
Continue Reading
On March 19, it was announced that chloroquine and hydroxychloroquine were showing promise in the treatment for COVID 19. However, there are no available data from randomized clinical trials to support efficacy, and taking these medications for COVID 19 is not recommended. A recent New York Times Article has noted that a University of Utah…
Continue Reading
Tom Lloyd, MD PhDAssociate Professor of Neurology and Neuroscience at Johns Hopkins University, Co-Director of the Johns Hopkins Myositis Center In a press conference today, President Trump discussed what the FDA was doing to accelerate approval of treatments for the novel coronavirus, COVID-19. Chloroquine, a drug that has been used since World War II to…
Continue Reading
Coronavirus disease also known as (COVID-19) is a respiratory illness that can spread from person to person. Symptoms include fever, cough, shortness of breath. The virus can lead to pneumonia in both lungs. Those who are immunosuppressed and/or elderly are particularly vulnerable to COVID-19 according to Dr. Rohit Aggarwal, Associate Professor of Medicine, Medical Director, Arthritis and…
Continue Reading
A recent article published in the Courier Newsroom discussed the challenges of caring for those with chronic illnesses and the economic and financial burdens that families face when dealing with debilitating disease. “Studies indicate that more than half of older Americans will eventually require long-term care, with the average lifetime long-term care costs for Americans…
Continue Reading